PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Crude root extract fractions showed antiproliferative activity against human prostate cancer DU-145 cells [PMID:39304868]
Methanolic crude extract showed high inhibitory activity against Mycobacterium tuberculosis, Escherichia coli, Staphylococcus aureus, and Candida albicans [PMID:33083626]
Leaf extracts demonstrated antiviral activity against human immunodeficiency virus type-1 with a selectivity index higher than 1 [PMID:11924766]
Specific ent-kaurane-type diterpenoids exhibited cytotoxicity against the Hep-G2 cell line [PMID:30518152]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 39304868 (2024) — Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. · BMC complementary medicine and therapies
- 2.PMID: 33563333 (2021) — In vitro cytotoxicity of Aspilia pluriseta Schweinf. extract fractions. · BMC research notes
- 3.PMID: 33083626 (2020) — Antimicrobial activity, phytochemical characterization and gas chromatography-mass spectrometry analysis of Aspilia pluriseta Schweinf. extracts. · Heliyon
- 4.PMID: 11924765 (2002) — Complement modulating activity of Rwandan medicinal plants. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 5.PMID: 11924766 (2002) — Antiviral activity of Rwandan medicinal plants against human immunodeficiency virus type-1 (HIV-1).